Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reata Pharmaceuticals, Inc.

http://www.reatapharma.com/

Latest From Reata Pharmaceuticals, Inc.

Flat Is The New Up As Biogen Anticipates Stabilizing Product Revenue In 2024

With its multiple sclerosis legacy under various pressures but four new drugs in indications outside of MS, the company expects flat product revenue in 2024 after a 3.8% decline in 2023.

Growth Launches

Biogen’s Skyclarys Seals Important Next Step With EU Approval

Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.

Companies Launches

Biogen’s Singhal Offers A Look Into Company's Pipeline Review

Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.

Growth Clinical Trials

Less Than First: Below-Average Innovation In US FDA’s Big 2023 Novel Approval Haul

Innovation metrics like first-in-class and breakthrough therapy approvals declined as a share of novel agents in 2023, even as the US FDA’s drugs center posted one of its biggest novel approval totals ever.

Approvals US FDA Performance Tracker
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register